Stay updated on SubQ Efgartigimod in CIDP Clinical Trial
Sign up to get notified when there's something new on the SubQ Efgartigimod in CIDP Clinical Trial page.

Latest updates to the SubQ Efgartigimod in CIDP Clinical Trial page
- Check2 days agoChange DetectedA sitewide NIH notice was added above the ClinicalTrials.gov navigation, announcing a terminology transition from “Artificial Intelligence” to “Super Intelligence” and linking to updates and FAQs. The study page continues to display a 403 error.SummaryDifference1%

- Check9 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.1 to v3.7.2 while the page continued to show a 403 error.SummaryDifference0.2%

- Check16 days agoChange DetectedThe footer revision label changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check30 days agoChange DetectedThe study page now displays a 403 Forbidden error instead of the study details, indicating access to the record is blocked or unavailable.SummaryDifference16%

- Check37 days agoChange DetectedThe page's revision label was updated to v3.7.0, indicating a newer version of the page metadata.SummaryDifference0.0%

- Check58 days agoChange DetectedA funding attribution for the NIH grant/contract was added to the study record, and the page revision was updated to v3.6.6 (replacing v3.6.5).SummaryDifference0.0%

Stay in the know with updates to SubQ Efgartigimod in CIDP Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SubQ Efgartigimod in CIDP Clinical Trial page.